



NovoBiome labelled French Tech Seed by the AgriO committee

The French Tech Seed label means NovoBiome is eligible for public funding to accelerate its growth and development

The label validates NovoSift®, NovoBiome's disruptive ex-vivo discovery platform

Paris, France – 4 August 2021: NovoBiome ("the Company"), a drug discovery company focused on the critical nexus of liver, intestinal diseases and the gut microbiome, announces that the AgriO Committee has labelled NovoBiome a 'French Tech Seed', paving the way for NovoBiome to receive additional public funding to accelerate the Company's growth and development.

The members of the AgriO consortium include The French National Research Institute for Agriculture, Food and Environment (INRAE), Montpellier SupAgro, Agronov, Vitagora, IAR and Agri Sud-Ouest Innovation, all of which are major players in the agricultural and food sectors. The aim of the consortium is to encourage the emergence of technology-intensive start-ups looking for financing, and to label those with the greatest potential with the sector-specific AgriO certification to aid networking with private investors.

In addition, the French Tech Seed label makes NovoBiome eligible to receive financing from Bpifrance. Established in 2013, Bpifrance is a trusted partner for entrepreneurs, offering a continuum of solutions adapted to every key step in a business' growth.

Pierre-Yves Mousset, Chief Executive Officer of NovoBiome, said: *"We are thrilled to have obtained this recognition by AgriO, which validates the potential of our disruptive ex-vivo discovery platform. Moreover, it confirms the interest in the field of intestinal microbiota, witnessing the close links between the two universes of health, and food and nutrition."*



-End-

About NovoBiome

NovoBiome is a drug discovery company focused on the critical nexus of liver, intestinal diseases and the gut microbiome. It is developing breakthrough Live Biotherapeutics Products (LBPs), a novel and emerging class of drugs containing living micro-organisms that have a positive influence on the health and physiology of the host. NovoBiome's first LBP drug candidate, ADC-001, targets potential first-in-class therapies for hepatic conditions such as Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH). The Company is developing an ex-vivo research and discovery platform, NovoSift®, designed to mimic human intestinal physiology that will unlock new insights into disease pathophysiology, novel drug targets, compounds and LBP drug candidates. NovoBiome is headquartered in France.

For more information, please visit: www.novobiome.eu

Contact

NovoBiome

Pierre-Yves Mousset, Chief Executive Officer

+33 (0) 616 310 400

py.mousset@novobiome.eu

Consilium Strategic Communications

Amber Fennell, Carina Jurs, Genevieve Wilson

+44 (0) 203 709 5000

eurekare@consilium-comms.com